Special Issue "Melanoma: Pathology and Translational Research"

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Pathophysiology".

Deadline for manuscript submissions: 20 April 2024 | Viewed by 148

Special Issue Editors

1. Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN 55455, USA
2. Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA
Interests: dermatopathology; melanoma; receptor tyrosine kinase; met; hgf; histopathology
Special Issues, Collections and Topics in MDPI journals
MD Anderson Cancer Center, The University of Texas, Houston, TX 77030, USA
Interests: cutaneous tumors; lymphomas; melanoma; pathology
Special Issues, Collections and Topics in MDPI journals
Dr. Jose A. Plaza
E-Mail Website
Guest Editor
Department of Pathology and Dermatology, The Ohio State University Wexner Medical Center (OSUWMC), Columbus, OH 43221, USA
Interests: pigmented skin lesions; adnexal skin neoplasms; immunohistochemistry in cutaneous tumors

Special Issue Information

Dear Colleagues,

We are excited to announce a Special Issue of Cancers, “Melanoma: Pathology and Translational Research”, dedicated to advancing our understanding of melanoma through the lens of pathology and translational research. Melanoma is a challenging malignancy, and insights from both the laboratory and clinical research are essential to driving progress in diagnosis and treatment.

This Special Issue aims to showcase the latest developments in the field of melanoma research, with a specific focus on how pathology and translational research intersect. We invite original research articles and reviews exploring various aspects of melanoma, including the histopathologic characterization of melanoma subtypes, the molecular and genetic profiling of melanoma, the identification of prognostic and predictive biomarkers, innovative diagnostic approaches, translational studies, and the use of novel technologies like digital pathology and artificial intelligence in the assessment of melanoma.

This Special Issue offers a unique opportunity to contribute to the advancement of melanoma research. We encourage researchers, clinicians, and pathologists to submit their work and help shape the future of melanoma diagnosis and treatment.

Dr. Alessio Giubellino
Dr. Carlos Torres-Cabala
Dr. Jose A. Plaza
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • melanoma
  • histopathology
  • dermatopathology
  • molecular profiling
  • biomarkers
  • digital pathology
  • translational studies
  • cancer therapy

Published Papers

This special issue is now open for submission.
Back to TopTop